Skip to main content
. 2011 Jun 17;12(5):551–559. doi: 10.1007/s10194-011-0358-9

Fig. 2.

Fig. 2

Individual and mean (filled square) flow velocities (cm/s) in the middle cerebral arteries (VMCA) on placebo day compared with BGC20-1531 before and after Prostaglandin E2 (PGE2) infusion. There was no difference between AUCVMCA on placebo and BGC20-1531 200 or 400 mg pretreatment (paired t test)